ozra tabatabaei

Recent evidence has shown underlying roles of gut dysbiosis and metabolic endotoxemia in obesity and its complications. Despite the large number of experimental and clinical researches performed on gut microbiota and obesity, no bibliometrics’ study has been conducted so far. We aimed to assess the trend of global scientific publications in the field of gut microbiota and obesity. The bibliometrics’ data from January 2000 to April 2017 were retrieved based on Scopus database. The analysis of the publication year, main source, citation, subject area, co-authorship network, and geographical distribution were carried out, accordingly. The data were analyzed using the Scopus analysis tools, SPSS version 15 and Visualizing Scientific Landscapes (VOS) viewer version 1.6.5. Out of 4384 documents that were identified, the United States published the highest number (28.2%), followed by China and United Kingdom. The number of publications showed an increasing trend over the years of which the most productive year was 2016. The leading subject area was medicine. Most of published scientific documents were original articles and the top source was “PLoS One”. The documents were cited totally 153576 times with average citations per article as 35.03, and h-index of 159. Top author in the co-authorship network assessment was “Wang J.” from China. This study could provide practical sources to researchers to find highly cited studies. Moreover, the study could pave the way for researchers to be engaged in studies which potentially lead to more publication in the field

Obesity is currently considered as a serious global health problem which is influenced by environmental and genetic factors. Association of genetic variants with obesity is widely scrutinized in recent years. The aim of this study was to evaluate present data on genetics of obesity in Iranian population in a systematic review study. To obtain all related studies, Google Scholar, PubMed, and Persian web databases; IranMedex and Magiran were searched up to January 2013. The search terms were; “gene”, “polymorphism, “obesity”, “waist circumference”, “BMI” affiliated to Iran. Non-population cross sectional studies, experimental studies, in vitro studies, case reports, review articles, letters to editor, short communications and dissertations were excluded. Finally 11 articles that investigated association of different gene variants with obesity were included. Due to the heterogeneity of data, it was impossible to perform a Meta-analysis. Our study showed that males with TT genotype for +45T>G variant of adiponectin gene, GG genotype for -11391G>A polymorphism of adiponectin, GC+GG genotype for Pro12Ala PPARγ2 gene variant, 1484insG carriers of PTP1B and AA genotype of 4223A>C ADA gene variant had significant positive association with obesity in Iranian population. However gene variants of glucokinase, TNF-α, UCP2, MTHFR, β3-adrenoreceptor and apolipoprotein E were not significantly associated with obesity. There are discrepancies in association between obesity and genetic variants in Iranian population compared to other populations. Therefore we suggest large scale genome wide association studies on defined populations with distinct clinical features are necessary in future to further investigate underlying genetic variants associated with obesity in Iranian population.

Despite the current existence and availability of synthetic drugs for the treatment of diabetes mellitus (DM), these medications are neither cheap nor completely effective. Furthermore, the long-term consumption of synthetic drugs may cause adverse effects, while those medications provided from natural sources are more affordable and have shown lesser adverse effects. The current belief is that oxidative stress plays a substantial role in the pathogenesis of diabetes and its complications. The characteristics of DM as a multifactorial disease are related to a deficit in the β-cells of the pancreas that results in defective production and release of insulin. Antioxidant therapy can protect β-cells from apoptosis and preserve their function. Therefore, the higher the antioxidant effects a compound might have, the higher the positive effects in diabetes anticipated. Our idea is that a combination of strong antioxidants might positively work in control of hyperglycemia by activating the production and release of insulin to the blood. In this scenario, if the strongest multi-herbal antioxidant complex called Setarud (IMOD™) is combined with curcumin and quercetin, then much stronger antioxidant activity with positive effects in the control of diabetes would be produced. To prove the idea, this combination has to be pharmaceutically prepared and then its safety and efficacy must be examined in preclinical and clinical studies.

Desmoperssin is the drug of choice for treatment of central diabetes insipidus and most commonly it is used as intranasal spray. In this study, efficacy and side effects of oral desmopressin was compared with the intranasal spray. This study was before -after clinical trial on 14 outpatients (9 F, 5 M, age 14 -50 Y) with central diabetes insipidus who had been treated with intranasal spray of desmopressin previously. Weight, pulse rate and blood pressure (sitting -standing), biochemical profile, serum electrolytes, 24h urine volume, specific gravity of urine and LFT was measured before and after 1 month study. Starting dose for each patient was one oral tablet of DDAVP (0.1 mg) per 8 hours. Paired Samples T-Test was used for data analysis. No clinically significant changes were found as regard to weight, pulse rate, blood pressure, blood chemistry, electrolyte and urinalysis. Single reported adverse effect was headache (43%) in tablet group and dyspnea (7%) in spray group. Both dosage forms were able to control diurnal polyuria and nocturnal polyuria. The antidiuretic dose - equivalence ratio for intranasal to oral desmopressin was 1: 18. Spray was superior in terms of rapid onset of action and duration of antidiuretic action in 100% and 78% of cases (not significant), respectively. Tablets were more available and much more easily consumed as reported by patients, in 86% (P=0.0006). Treatment with tablets offers a good alternative to the intranasal route, especially in patients with chronic rhinitis or common cold and similar conditions.

Since by considering increases worldwide prevalence of diabetes mellitus, and its management in the short and long–term requires significant expenditure on the part of patients and healthcare providers alike, and on the other hand existing resources fall short of the country's needs in this domain, diabetes has become one of the major health priorities in our country, as it has across the globe. Assessment of injuries due to diabetes mellitus and complications are divided to two sections: 1– economic cost of diabetes mellitus and 2 – burden of diabetes mellitus. In this study we assessed burden of diabetes mellitus and complications in Iran in year 2000. We used ten years ago studies about prevalence of diabetes and complications in Iran, associated DALYs index by helping computer model (DisMod) for assessment of burden of diabetes and complications in Iran in year 2000. Burden of diabetes in Iran was 306440 years in year 2000. Burden of diabetic retinopathy, nephropathy, neuropathy, diabetic foot and lower limb amputation were 20532, 20532, 33286, 5848 and 1573 years, respectively. Pay attention to this study, we will need to reduce diabetes's burden by setting serious programs about prevention and treatment of diabetes mellitus and complications. Thus, we suggest, other studies are planning for assessment of burden of other diseases. Then after comparing burden of diabetes to other diseases, government politicians are performance priorities setting for using of our country resource.

Since by considering increases worldwide prevalence of diabetes mellitus, and its management in the short and long-term requires significant expenditure on the part of patients and healthcare providers alike, and on the other hand existing resources fall short of the country's needs in this domain, diabetes has become one of the major health priorities in our country, as it has across the globe. Assessment of injuries due to diabetes mellitus and complications are divided to two sections: 1- economic cost of diabetes mellitus and 2 - burden of diabetes mellitus. In this study we assessed burden of diabetes mellitus and complications in Iran in year 2000.
We used ten years ago studies about prevalence of diabetes and complications in Iran, associated DALYs index by helping computer model (DisMod) for assessment of burden of diabetes and complications in Iran in year 2000.
Burden of diabetes in Iran was 306440 years in year 2000. Burden of diabetic retinopathy, nephropathy, neuropathy, diabetic foot and lower limb amputation were 20532, 20532, 33286, 5848 and 1573 years, respectively.
Pay attention to this study, we will need to reduce diabetes's burden by setting serious programs about prevention and treatment of diabetes mellitus and complications. Thus, we suggest, other studies are planning for assessment of burden of other diseases. Then after comparing burden of diabetes to other diseases, government politicians are performance priorities setting for using of our country resource.

Gliclazide is a second generation sulfonylurea which its efficacy and safety in the treatment of diabetes has been established. Diamicron MR (30 mg) is a new formulation of gliclazide with modified release which offer once daily dosage administration. This study was designed to assess the effect of combination therapy with diamicron and metformin in the treatment of type 2 diabetes. 16 patients with type 2 diabetes (2 males, 14 females) more than 35 years old who despite treatment with glibenclamide and metformin had poor diabetes control participated in this clinical trial.HbA1c, lipid profile, liver and renal function tests at the end of study were compared with before. No significant changes was found in FBS, BS2hpp, lipid profile and renal and liver function tests at the end of study. Patient's weight was stable during the study. Regardless of well efficacy of diamicron in the treatment of new diabetics cases, it is not recommended for patients with poor diabetes control despite of combination therapy with metformin and glibenclamide.

Gliclazide is a second generation sulfonylurea which its efficacy and safety in the treatment of diabetes has been established. Diamicron MR (30 mg) is a new formulation of gliclazide with modified release which offer once daily dosage administration. This study was designed to assess the effect of combination therapy with diamicron and metformin in the treatment of type 2 diabetes.
16 patients with type 2 diabetes (2 males, 14 females) more than 35 years old who despite treatment with glibenclamide and metformin had poor diabetes control participated in this clinical trial.HbA1c, lipid profile, liver and renal function tests at the end of study were compared with before.
No significant changes was found in FBS, BS2hpp, lipid profile and renal and liver function tests at the end of study. Patient's weight was stable during the study.
Regardless of well efficacy of diamicron in the treatment of new diabetics cases, it is not recommended for patients with poor diabetes control despite of combination therapy with metformin and glibenclamide.